Purple Biotech Ltd (TLV:PPBT)
Israel
· Delayed Price · Currency is ILS · Price in ILA 4.000
-0.100 (-2.44%)
May 29, 2025, 5:24 PM IDT
Purple Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cost of Revenue | 0.06 | 0.06 | 0.2 | 0.12 | 0.06 | 0.06 | Upgrade
|
| Gross Profit | -0.06 | -0.06 | -0.2 | -0.12 | -0.06 | -0.06 | Upgrade
|
| Selling, General & Admin | 2.72 | 3.12 | 5.04 | 6.16 | 6.04 | 5.9 | Upgrade
|
| Research & Development | 4.96 | 7.62 | 17.03 | 16.32 | 11.83 | 7.24 | Upgrade
|
| Operating Expenses | 7.68 | 10.74 | 22.08 | 22.48 | 17.87 | 13.14 | Upgrade
|
| Operating Income | -7.74 | -10.8 | -22.27 | -22.6 | -17.92 | -13.2 | Upgrade
|
| Interest & Investment Income | 0.22 | 0.26 | 0.47 | 0.53 | 0.32 | 0.25 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.01 | -0.01 | 0.06 | -0.13 | -0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.8 | 3.48 | 1.83 | 0.25 | -0.08 | -15.71 | Upgrade
|
| EBT Excluding Unusual Items | -3.75 | -7.08 | -19.98 | -21.76 | -17.81 | -28.66 | Upgrade
|
| Asset Writedown | -0.2 | -0.2 | - | - | - | - | Upgrade
|
| Legal Settlements | - | - | - | - | -0.01 | -0.04 | Upgrade
|
| Pretax Income | -3.95 | -7.28 | -19.98 | -21.76 | -17.83 | -28.7 | Upgrade
|
| Earnings From Continuing Operations | -3.95 | -7.28 | -19.98 | -21.76 | -17.83 | -28.7 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | -0.64 | 0.63 | Upgrade
|
| Net Income to Company | -3.95 | -7.28 | -19.98 | -21.76 | -18.47 | -28.07 | Upgrade
|
| Minority Interest in Earnings | 0.02 | 0.04 | 0.1 | 0.09 | 0.08 | 0.08 | Upgrade
|
| Net Income | -3.93 | -7.24 | -19.88 | -21.67 | -18.38 | -28 | Upgrade
|
| Net Income to Common | -3.93 | -7.24 | -19.88 | -21.67 | -18.38 | -28 | Upgrade
|
| Shares Outstanding (Basic) | 328 | 328 | 221 | 181 | 176 | 115 | Upgrade
|
| Shares Outstanding (Diluted) | 328 | 328 | 221 | 181 | 176 | 115 | Upgrade
|
| Shares Change (YoY) | 37.04% | 48.17% | 22.41% | 2.92% | 52.76% | 493.78% | Upgrade
|
| EPS (Basic) | -0.01 | -0.02 | -0.09 | -0.12 | -0.10 | -0.24 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.02 | -0.09 | -0.12 | -0.10 | -0.24 | Upgrade
|
| Free Cash Flow | -11.26 | -14.37 | -19.93 | -16.76 | -15.37 | -12.25 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.04 | -0.09 | -0.09 | -0.09 | -0.11 | Upgrade
|
| EBITDA | -7.71 | -10.77 | -22.23 | -22.4 | -17.69 | -12.96 | Upgrade
|
| D&A For EBITDA | 0.03 | 0.03 | 0.05 | 0.2 | 0.23 | 0.24 | Upgrade
|
| EBIT | -7.74 | -10.8 | -22.27 | -22.6 | -17.92 | -13.2 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.